The B16 Mgst1 KD tumor becomes more immunogenic than B16 NT tumor, with significantly reduced expression of negative, costimulatory molecules (PD1, KLRG1, LAG3, and TIM3 correlating with T-cell exhaustion or dysfunction (33)) in CD8+ T cells retrieved from B16 Mgst1 KD tumor; there was also an increase in cytokine response (IFNγ and TNFα) along with Granzyme B. Therefore, we conclude that tumor-induced immunosuppression is reduced with the Mgst1 KD strategy. The gene discussed is GZMB; the disease is neoplasm.